Rituximab therapy for Anti-IFN-γ Autoantibody Immunodeficiency (AIGA) evaluated in a Hong Kong cohort using pStat1 assays.
Prospective Registry of Outcomes, Treatment, and Clinical Trajectories for Anti-IFN-γ Immunodeficiency.
Abstract
A longitudinal cohort study in Hong Kong recruited 38 patients with Anti-IFN-γ Autoantibody Immunodeficiency (AIGA) to evaluate rituximab therapy and the utility of pStat1 neutralization assays.